Elsevier

The Journal of Pediatrics

Volume 243, April 2022, Pages 208-213.e3
The Journal of Pediatrics

Brief Reports
mRNA Coronavirus Disease 2019 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study

https://doi.org/10.1016/j.jpeds.2021.12.025Get rights and content

In this survey study of institutions across the US, marked variability in evaluation, treatment, and follow-up of adolescents 12 through 18 years of age with mRNA coronavirus disease 2019 (COVID-19) vaccine-associated myopericarditis was noted. Only one adolescent with life-threatening complications was reported, with no deaths at any of the participating institutions.

Keywords

mRNA COVID-19 vaccine-associated myopericarditis
survey
variability
outcomes

Abbreviations

COVID-19
Coronavirus disease 2019
IVIG
Intravenous immunoglobulin
NSAID
Nonsteroidal anti-inflammatory drug
PCR
Polymerase chain reaction
VAERS
Vaccine Adverse Event Reporting System
VAM
Vaccine-associated myopericarditis

Cited by (0)

Affiliation information is available at www.jpeds.com.

A.H. is supported by a Sub-agreement from the Johns Hopkins University with funds provided by R61HD105591 from the Eunice Kennedy Shriver National Institute of Child Health & Human Development and the Office of the Director, National Institute of Health (OD). This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Eunice Kennedy Shriver National Institute of Child Health & Human Development, the Office of the Director, National Institutes of Health (OD), the National Institutes of Health, the National Institute of Biomedical Imaging and Bioengineering, the National Heart, Lung, and Blood Institute, or the Johns Hopkins University. The authors declare no conflicts of interest.

View Abstract
© 2021 Elsevier Inc. All rights reserved.